Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2[1][2][3][4].
Molecular Weight:
354.38
Purity:
99.92
CAS Number:
[1948241-60-8]
Formula:
C14H18N4O5S
Target:
HBV,SARS-CoV,Toll-like Receptor (TLR)
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted